



## CD289 Antibody [72-1665] (PE)

CATALOG NUMBER: 76-971

### Specifications

<b>SPECIES REACTIVITY:</b>	Human
<b>TESTED APPLICATIONS:</b>	FACS
<b>USER NOTE:</b>	Optimal dilutions for each application to be determined by the researcher.
<b>SPECIFICITY:</b>	The 72-1665 monoclonal antibody specifically reacts with CD289, also known as human toll-like receptor 9 (TLR9).
<b>HOST SPECIES:</b>	Rat

### Properties

<b>PURIFICATION:</b>	The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
<b>PHYSICAL STATE:</b>	liquid
<b>BUFFER:</b>	Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, pH7.2.
<b>CONCENTRATION:</b>	0.2 mg/mL
<b>STORAGE CONDITIONS:</b>	The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze.
<b>CLONALITY:</b>	Monoclonal
<b>ISOTYPE:</b>	Rat IgG2a, kappa
<b>CONJUGATE:</b>	PE

### Additional Info

<b>ALTERNATE NAMES:</b>	TLR9, TLR9
<b>OFFICIAL SYMBOL:</b>	TLR9
<b>GENE ID:</b>	54106

### Background

<b>BACKGROUND:</b>	The 72-1665 monoclonal antibody specifically reacts with CD289, also known as human toll-like receptor 9 (TLR9). CD289 is involved in the activation of innate immunity, in acquired immune responses, and autoimmune diseases. It is involved in the immune system's response to unmethylated CpG dinucleotide sequences such as those found in bacterial, viral, or synthetic DNA. CD289 assists in pathogen recognition and is expressed by subtypes of dendritic cells and B cells.
<b>REFERENCES:</b>	<p>1) Zhang, J. Y., Zhang, Z., Wang, X., Fu, J. L., Yao, J., Jiao, Y., ... Wang, F. S. (2007). PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. <i>Blood</i>, 109(11), 4671-4678.</p> <p>2) Bennett, F., Luxenberg, D., Ling, V., Wang, I. M., Marquette, K., Lowe, D., ... Carreno, B. M. (2003). Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. <i>The Journal of Immunology</i>, 170(2), 711-718.</p> <p>3) Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., Kwon, E. D. (2007).</p>

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. *Clinical Cancer Research*, 13(6), 1757-1761.

---

**FOR RESEARCH USE ONLY**

December 13, 2016